Category: biotech

.Professional venture capital agency venBio has actually lifted an additional half a billion bucks to invest in biotechs working on diseases with unmet necessity. The

.After declaring a phase 3 launch based on beneficial midstage outcomes, iTeos and also GSK are eventually sharing the highlights from the period 2 TIGIT

.Otsuka Pharmaceutical’s renal disease drug has attacked the primary endpoint of a period 3 test through demonstrating in an acting study the decline of people’

.Zevra Therapies’ rare health condition drug appears to become on the path to confirmation this autumn after gaining the support of an FDA advising committee,

.Bicara Rehabs and also Zenas Biopharma have provided new inspiration to the IPO market with filings that highlight what recently social biotechs might resemble in

.Chief executive officer David Ricks can see the providers putting together tents at basecamp responsible for Eli Lilly in a try to get a niche

.After raising $213 million in 2023– among the year’s most extensive private biotech shots– Tome Biosciences is helping make cuts.” Even with our clear medical

.As biotechs seek to transform a new web page in August, at least three providers have lost team in tries to forge on. First up

.OncoC4 is taking AcroImmune– and also its internal scientific manufacturing capabilities– under its fly an all-stock merging.Both cancer biotechs were actually co-founded by OncoC4 CEO

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock exchange, submission (PDF) for an IPO to bankroll period 3 trials of its own cell